# Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

> **NCT00193557** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 40 (—)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00193557
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-05
- **Final completion:** 2009-01
- **Target enrollment:** 40 (—)
- **Last updated:** 2010-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193557, "Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00193557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*